Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin

Wenxia Hu\textsuperscript{a} Pule Jin\textsuperscript{a} Wei Liu\textsuperscript{b}

\textsuperscript{a}Department of Respiratory Medicine, the Fourth Hospital of Hebei Medical University, Shijiazhuang, \textsuperscript{b}Department of Oncology, Hebei Medical University, Shijiazhuang, China

Key Words
Chemoresistance • Lung cancer • Periostin • Stat3 signaling • Therapeutic target

Abstract

Background/Aims: Periostin is upregulated in non-small cell lung cancer (NSCLC). This study was done to explore the function of periostin in the development of cisplatin (CDDP) resistance in NSCLC. Methods: The effects of overexpression or knockdown of periostin on CDDP sensitivity was examined in A549 cells. The involvement of signal transducer and activator of transcription 3 (Stat3) and Akt signaling in the action of periostin was checked. The in vivo effect of periostin silencing on CDDP susceptibility was determined in a mouse xenograft model. Results: Periostin was significantly upregulated in CDDP-resistant A549 cells, compared to parental controls. Overexpression of periostin rendered A549 cells more resistant to CDDP-induced apoptosis and enhanced Stat3 and Akt phosphorylation and survivin expression. Periostin-mediated protection against CDDP-induced apoptosis was compromised by downregulation of survivin. Furthermore, knockdown of periostin re-sensitized CDDP-resistant A549 cells to CDDP. After CDDP treatment, greater volume reduction was observed in periostin-silenced xenograft tumors than in control tumors, which was accompanied by reduced levels of phosphorylated Stat3 and survivin in periostin-depleted tumors. Conclusion: In conclusion, periostin promotes CDDP resistance in NSCLC cells largely through activation of Stat3 and Akt and upregulation of survivin and thus represents a promising target for overcoming CDDP resistance.

Introduction

Non-small cell lung cancer (NSCLC), accounting for about 80% of all lung cancer cases, is one of the leading causes of cancer-related mortality in the world [1]. Most NSCLC patients are diagnosed at locally advanced or metastatic disease stage and have a dismal prognosis,
with the overall 5-year survival rate of 20% [2]. Cisplatin (CDDP)-based chemotherapy is currently the first-line therapy for non-resectable or advanced NSCLC. However, emergence of chemoresistant tumor cells ultimately leads to therapeutic failure. Drug efflux, enhancement of DNA repair activity, defects in cell death pathways, and activation of pro-survival signaling pathways have been suggested to contribute to CDDP resistance in tumor cells [3, 4]. Identification of key mediators of CDDP resistance is of importance in improving the efficacy of chemotherapy against NSCLC.

Periostin, originally identified as an osteoblast-specific factor [5], has been found to be overexpressed in various types of human cancers including NSCLC [6]. Periostin plays a critical role in tumor cell survival. Bao et al. [7] reported that periostin confers protection against stress-induced apoptosis in colon cancer cells. In another study by this research group, periostin shows the ability to augment the survival of A549 NSCLC cells under hypoxic conditions [8]. A recent study has shown that periostin induces chemoresistance in colon cancer cells [9]. These studies suggest periostin as a novel survival factor for cancer cells.

Therefore, in this study, we aimed to explore the possible role of periostin in the development of CDDP resistance in NSCLC cells. Signal transducer and activator of transcription 3 (Stat3) signaling is constitutively activated and associated with chemoresistance in NSCLC [10]. Inhibition of Stat3 signaling has been documented to sensitize A549 NSCLC cells to DNA damaging drugs doxorubicin and CDDP [11]. Akt signaling is also involved in the chemoresistance of A549 cells to CDDP [12, 13]. We thus tested the involvement of Stat3 and Akt signaling in the activity of periostin.

Materials and Methods

Cell culture

Human NSCLC A549 cells (originated from lung adenocarcinoma) were purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China) and maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 100 μg/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS; Invitrogen) at 37°C in a humidified atmosphere with 5% CO₂. The CDDP-resistant A549 cell line (A549/CDDP) was established by exposure to increasing concentrations (0.5, 1, 4, 10, and 20 μM) of CDDP (Sigma-Aldrich, St. Louis, MO, USA). At each concentration, A549 cells were allowed to grow for 2 weeks. The CDDP-resistant cells were maintained in the medium containing 10 μM of CDDP.

MTT assay

Cells were seeded in triplicate onto 96-well plates at a density of 5 × 10³ cells per well and incubated with different concentrations of CDDP ranging from 0 to 30 μM for 48 h. The cell culture was added with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) solution (Sigma-Aldrich) at a final concentration of 0.5 mg/mL and incubated for additional 4 h at 37°C. Dimethyl sulfoxide (DMSO; Sigma-Aldrich) was added to each well to dissolve the formazan product. Absorbance was measured at a wavelength of 570 nm. The concentration-cell viability curve was plotted, from which the half-maximal inhibitory concentration (IC50) was estimated.

Plasmids, short hairpin RNAs (shRNA), and cell transfection

For construction of a periostin-expressing plasmid [14], full-length human periostin cDNA (OriGene, Rockville, MD, USA) was amplified by PCR and subcloned into pcDNA3.1 (+) vector (Invitrogen). The identity of the resulted plasmid (pcDNA3.1/periostin) was confirmed by DNA sequencing. Periostin- and survivin-targeting shRNAs as well as negative control shRNAs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

For transfection experiments, cells were seeded onto 6-well plates (5 × 10⁵ cells/well) the day before transfection. Cells were transfected with pcDNA3.1(+) empty vector (0.5 μg), pcDNA3.1/periostin plasmid (0.5 μg), or together with survivin or control shRNAs (1 μg for each shRNA) using the Lipofectamine 2000
transfection reagent (Invitrogen) according to the manufacturer’s instructions. At 24 h after transfection, cells were harvested for gene expression analysis or exposure to CDDP for 48 h before further assays.

For generation of stable periostin knockdown cells, periostin-specific shRNA or control shRNAs were transfected into A549/CDDP cells. Transfected cells were selected for 2 weeks in the presence of 0.5 mg/mL of G418 (Sigma-Aldrich). G418-resistant cells were pooled and used in the subsequent experiments.

Quantitative real-time PCR (qRT-PCR) analysis
Periostin mRNA levels were measured using qRT-PCR analysis, as described previously [15]. In brief, total cellular RNA was isolated using Trizol reagents (Invitrogen) and reversely transcribed to first-strand cDNA using TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA, USA). PCR amplifications were carried out on an ABI 7900 TaqMan Sequence Detection System (Applied Biosystems). The sequences of the PCR primers used were as follows: human periostin forward, 5′-GCG CTT TAG CAC CTT CCT-3′ and reverse, 5′-GCA CAA ATA ATG TCC AGT CTCC-3′; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward, 5′-CGA CCA CTT TGT CAA GCTCA-3′ and reverse, 5′-AGG GGT CTA CAT GTC AACTG-3′. The relative periostin mRNA expression was determined according to the 2^−ΔΔCt method after normalization against GAPDH [16].

Western blot analysis
Cells were lysed in Radio-immuno-protein assay (RIPA) buffer (Thermo Scientific, Rockford, IL, USA) containing Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA). Protein samples (20 µg per lane) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked with 5% non-fat milk in 1 × TBST (10 mM Tris-HCl, 150 mM NaCl, pH 8.0, and 0.1% Tween 20), and incubated with primary antibodies overnight at 4°C. The primary antibodies included: anti-periostin (sc-67233, Santa Cruz Biotechnology), anti-cleaved caspase-3 (#9661), anti-phospho-Stat3 (#9131), anti-Stat3 (#12640), anti-phospho-Akt (#9271), anti-Akt (#9272), anti-survivin (#2803), and anti-β-actin (#8457, Cell Signaling Technology, Danvers, MA, USA). After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology). Membranes were developed using a chemiluminescence method (ECL, Amersham Biosciences, Piscataway, NJ, USA). Densitometric analysis of protein signals was conducted with Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).

Apoptosis detection by flow cytometry
Cell apoptosis was measured using the Annexin V-FITC Apoptosis Detection Kit (Sigma-Aldrich) according to the manufacturer’s protocol. After double staining with Annexin V-FITC and propidium iodide (PI), cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Animal experiments
All animal experiments were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care Committee of Hebei Medical University (Shijiazhuang, China). Female BALB/C nude mice (4- to 6-week-old) were purchased from Beijing University Experimental Animal Center (Beijing, China). Control shRNA- and periostin shRNA-transfected A549/CDDP cells (4 × 10^6) were subcutaneously injected into the left and right flank of each nude mouse, respectively. At 5 days after cell transplantation, the mice (4 mice per treatment group) were randomly assigned to receive an intraperitoneal injection of CDDP (5 mg/kg every 4 days) [17] or PBS. Tumor volume was measured every 5 days. At 30 days after cell transplantation, all mice were sacrificed. The tumors were removed and subjected to Western blot analysis.

Statistical analysis
Data are presented as means ± standard deviation. All statistical calculations were carried out using SPSS 11.7 software (SPSS, Chicago, IL, USA). Statistical differences among multiple groups were analyzed by one-way analysis of variance followed by the Tukey test. A P-value of < 0.05 was considered statistically significant.
Results

Periostin is upregulated in CDDP-resistant A549 cells

To confirm the development of acquired chemoresistance after stepwise exposure to increasing concentrations of CDDP, A549/CDDP and parental cells were treated with different concentrations of CDDP for 48 h and cell viability was measured by the MTT assay. As shown in Fig. 1A, the IC_{50} of A549/CDDP and A549 cells for CDDP was about 25 μM and 10 μM, respectively, indicating that A549/CDDP cells were more resistant to CDDP than A549 cells.

qRT-PCR analysis revealed that the expression level of periostin mRNA was approximately 6-fold greater in A549/CDDP cells than in A549 cells (P < 0.05; Fig. 1B). The induction of periostin expression in CDDP-resistant cells was confirmed at the protein level by Western blot analysis (Fig. 1C).

Periostin decreases the sensitivity of A549 cells to CDDP

Next, we sought to check if the upregulation of periostin affected the sensitivity of A549 cells to CDDP. As shown in Fig. 2A, transfection of periostin-expressing plasmid led to overexpression of periostin in A549 cells. After incubation with different concentrations of CDDP, periostin-overexpressing cells were more viable than empty vector-transfected cells (P < 0.05; Fig. 2B).

To further determine the effect of periostin on the sensitivity of A549 cells to CDDP, annexin-V/PI staining assay was performed to measure the apoptotic response after treatment with 10 or 30 μM CDDP for 48 h. As shown in Fig. 2C, periostin overexpression significantly (P < 0.05) decreased CDDP-induced apoptosis, compared with the control group. The apoptosis rate after treatment with 30 μM CDDP was 26.1 ± 1.2% and 9.5 ± 0.7% in control and periostin-overexpressing cells, respectively (Fig. 2C). The protection...
against CDDP-induced apoptosis by overexpression of periostin was also confirmed in an independent NSCLC cell line, H460 (data not shown). In addition, Western blot analysis was done to analyze caspase-3 cleavage, another indicator of apoptosis. We found that the levels of cleaved caspase-3 were significantly ($P < 0.05$) increased in parental A549 cells after CDDP treatment (Fig. 2D). Periostin overexpression significantly prevented the induction of cleaved caspase-3 by CDDP.

**Periostin-mediated CDDP resistance is linked to activation of Stat3 and Akt and upregulation of survivin**

Next, we tested the signaling pathways involved in periostin-mediated CDDP resistance. Western blot analysis showed that periostin overexpression did not affect the protein level of total Stat3 or Akt (Fig. 3A). However, Stat3 and Akt phosphorylation was enhanced by ectopic expression of periostin, irrespective of the presence or absence of CDDP (Fig. 3A). Stat3 activation has been shown to confer apoptosis resistance via regulation of survivin expression [18]. We found that CDDP treatment of A549 parental cells significantly reduced the level of survivin, compared to untreated cells (Fig. 3A). However, in periostin-overexpressing A549 cells, the level of survivin was elevated after CDDP treatment.

To examine the role of survivin in periostin-mediated apoptosis resistance to CDDP, we co-transfected A549 cells with periostin- and survivin shRNA-expressing plasmids before
exposure to CDDP and examined apoptosis response. As shown in Fig. 3B, co-transfection of survivin shRNA interfered with the antiapoptotic activity of periostin, partially restoring the apoptosis response to CDDP. Additionally, periostin-mediated inhibition of caspase-3 cleavage in CDDP-treated cells was reversed by co-transfection of survivin shRNA (Fig. 3C).

**Periostin silencing re-sensitizes CDDP-resistant A549 cells**

Having identified the contribution of periostin in CDDP resistance, we next checked whether targeting periostin could re-sensitize CDDP-resistant cells to this drug. As shown in Fig. 4A, shRNA-mediated silencing of periostin significantly decreased the viability of A549/CDDP cells after exposure to 10 or 30 µM CDDP, compared to control shRNA-transfected cells. Consistently, periostin downregulation restored a significant apoptotic response to CDDP (Fig. 4B). Mouse studies were performed to validate the effect of periostin depletion on CDDP sensitization in vivo. As shown in Fig. 4C, periostin-silenced xenograft tumors grew slowly than control tumors. At the end of the experiment, CDDP treatment significantly reduced the
volumes of control and periostin-silenced tumors to 56% and 21% of corresponding PBS-treated tumors, respectively (P < 0.05). Western blot analysis of resected xenograft tumors demonstrated that after CDDP treatment, periostin-depleted tumors expressed lower levels of phosphorylated Stat3 and survivin and higher amounts of cleaved caspase-3 than control tumors (Fig. 4D). These results indicate that periostin depletion re-sensitizes CDDP-resistant A549 cells to CDDP treatment and suppresses the activation of Stat3/survivin signaling in vivo.

**Discussion**

Although an initial response occurs after CDDP-based chemotherapy, many NSCLC patients will eventually develop resistance to such treatments [19]. To identify key mediators of CDDP resistance in NSCLC, we established a CDDP-resistant A549 cell model via stepwise exposure to increasing concentrations (0.5 to 20 μM) of CDDP. This model mimics clinical conditions under which NSCLC cells develop CDDP resistance.

Periostin has been identified as a hypoxia responsive gene in different cellular contexts such as pulmonary arterial smooth muscle cells [20] and NSCLC cells [8]. This gene shows the ability to promote the survival of cancer cells under hypoxic conditions [8]. Compelling evidence indicates that hypoxia is causally linked to chemoresistance in NSCLC. Schnitzer et al. [21] reported that hypoxia-induced upregulation of sphingosine kinase 2 contributes to chemoresistance in A549 cells via increased synthesis and release of sphingosine-1-phosphate, a bioactive lipid. Therefore, in this study, we sought to determine the role of CDDP resistance in NSCLC cells. Our data showed that periostin was significantly upregulated in...
CDDP-resistant A549 cells, suggesting its possible involvement in the acquisition of drug resistance. Chemotherapeutic drug-induced periostin expression has also been observed in colon cancer cells [9]. To test the hypothesis that upregulation of periostin may contribute to cell survival after exposure to chemotherapeutic drugs, we overexpressed periostin in A549 cells and measured changes in cell viability and apoptosis in response to CDDP treatment. We found that overexpression of periostin rendered A549 cells more resistant to CDDP, as evidenced by increased cell viability and reduced apoptotic response. Caspase-3 is a key mediator of the apoptosis pathway induced by CDDP [22]. Notably, ectopic expression of periostin inhibited CDDP-induced expression of active (cleaved) caspase-3 in A549 cells, suggesting that the anti-apoptotic effect of periostin involves prevention of caspase-3 activation. In agreement with our results, periostin has been previously reported to impair chemotherapeutic drug-induced activation of caspase-3 and apoptotic response in gastric cancer cells [23]. Taken together, our data highlight the importance of periostin in CDDP resistance of NSCLC cells, which is ascribed to its anti-apoptotic activity.

Several molecular pathways are involved in different functional aspects of periostin [24, 25]. Zhang et al. [24] demonstrated that periostin facilitates angiogenesis in keloids via activation of the ERK 1/2 and focal adhesion kinase (FAK) pathways. Yang et al. [25] reported that periostin promotes skin sclerosis through a PI3K/Akt-dependent mechanism in a mouse model of scleroderma. Activation of the Akt/PKB pathway has been shown to mediate the enhancement of colon cancer metastasis by periostin [7]. Stat3 signaling is implicated in chemoresistance of NSCLC cells and represents an important therapeutic target for NSCLC [10]. Pharmacological inhibition of the Jak/Stat pathway has been documented to overcome CDDP resistance in NSCLC [26]. Therefore, in this work, we investigated whether activation of Stat3 signaling was linked to periostin-mediated CDDP resistance. We showed that periostin overexpression induced the activation of Stat3 and Akt and the expression of survivin in A549 cells, even in the presence of CDDP. Moreover, depletion of survivin significantly attenuated the protective effect of periostin against CDDP cytotoxicity, as evidenced by increased apoptotic response and caspase-3 activation. Collectively, periostin confers protection against CDDP-induced apoptosis in NSCLC cells largely through activation of Stat3 and Akt and upregulation of survivin.

Inhibition of periostin has been documented to suppress tumor growth and metastasis in many cancers [27, 28]. For instance, Zhu et al. [27] reported that blockade of periostin activity using neutralizing monoclonal antibody results in reduced ovarian tumor growth and metastasis. Our in vitro and in vivo studies further confirmed the significance of periostin as a therapeutic target in chemoresistant NSCLC. We found that downregulation of periostin significantly re-sensitized A549/CDDP cells to CDDP treatment. In a mouse model, CDDP treatment yielded greater tumor volume reduction in periostin-silenced A549/CDDP xenograft tumors than in control tumors. Western blot analysis confirmed that the chemosensitizing effect of periostin silencing was associated with suppression of Stat3 activation and survivin expression. These results suggest that targeting periostin may represent a promising strategy for overcoming CDDP resistance in NSCLC.

Some limitations of this study should be noted. First, the effect of periostin on CDDP resistance was not tested in other types of cancer cells. It is unclear whether periostin-mediated CDDP resistance occurs in different types of cancers. Second, no information is available on the relationship between periostin levels and chemotherapeutic response in patients with NSCLC. Finally, the mechanism for periostin-induced activation of Stat3 is still elusive.

In conclusion, our data provide first evidence for the involvement of periostin in CDDP resistance in NSCLC cells. Periostin-mediated protection against CDDP-induced apoptosis is ascribed at least partially to activation of Stat3 and Akt and upregulation of survivin. Periostin may represent a potential target for improving chemotherapeutic efficacy in NSCLC.
Disclosure Statement

None.

References


